Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | Sep. 26, 2019 | |
Document Information [Line Items] | ||
Entity Registrant Name | AMYRIS, INC. | |
Entity Central Index Key | 0001365916 | |
Trading Symbol | amrs | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 103,400,207 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Title of 12(b) Security | Common Stock |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 | |
Current assets: | |||
Cash and cash equivalents | $ 5,153 | $ 45,353 | |
Restricted cash | 623 | 741 | |
Accounts receivable, net | 10,968 | 16,003 | |
Accounts receivable - related party, net | 1,334 | 1,349 | |
Accounts receivable, unbilled - related party | 8,021 | ||
Inventories | 8,486 | 9,693 | |
Deferred cost of products sold - related party | 1,489 | 489 | |
Prepaid expenses and other current assets | 8,215 | 10,566 | |
Total current assets | 36,268 | 92,215 | |
Property, plant and equipment, net | 21,558 | 19,756 | |
Accounts receivable, unbilled, noncurrent - related party | [1] | 1,203 | 1,203 |
Deferred cost of products sold, noncurrent - related party | 9,001 | 2,828 | |
Restricted cash, noncurrent | 960 | 960 | |
Recoverable taxes from Brazilian government entities | 2,964 | 3,005 | |
Right-of-use assets under operating leases (Note 2) | 27,645 | ||
Other assets | 5,548 | 7,958 | |
Total assets | 105,147 | 127,925 | |
Current liabilities: | |||
Accounts payable | 28,604 | 26,844 | |
Accrued and other current liabilities | 33,591 | 28,979 | |
Lease liabilities (Note 2) | 11,424 | ||
Contract liabilities | 8,333 | 8,236 | |
Debt, current portion (instrument measured at fair value $60,048 and $57,918, respectively) | 129,393 | 124,010 | |
Related party debt, current portion | 24,359 | 23,667 | |
Total current liabilities | 235,704 | 211,736 | |
Long-term debt, net of current portion | 42,928 | 43,331 | |
Related party debt, net of current portion | 19,147 | 18,689 | |
Lease liabilities, net of current portion (Note 2) | 18,850 | ||
Derivative liabilities | 3,798 | 42,796 | |
Other noncurrent liabilities | 16,920 | 23,192 | |
Total liabilities | 337,347 | 339,744 | |
Commitments and contingencies (Note 8) | |||
Mezzanine Equity | 5,000 | 5,000 | |
Stockholders’ deficit: | |||
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March 31, 2019 and December 31, 2018, and 14,656 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively | |||
Common stock - $0.0001 par value, 250,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 77,210,681 and 76,564,829 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively | 8 | 8 | |
Additional paid-in capital | 1,383,363 | 1,346,996 | |
Accumulated other comprehensive loss | (42,379) | (43,343) | |
Accumulated deficit | (1,579,129) | (1,521,417) | |
Total Amyris, Inc. stockholders’ deficit | (238,137) | (217,756) | |
Noncontrolling interest | 937 | 937 | |
Total stockholders' deficit | (237,200) | (216,819) | |
Total liabilities, mezzanine equity and stockholders' deficit | $ 105,147 | $ 127,925 | |
[1] | As of March 31, 2019 and December 31, 2018, contract liabilities, noncurrent is presented in Other Noncurrent Liabilities in the consolidated balance sheets because of its insignificance. |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Accounts receivable, allowance | $ 126 | $ 642 |
Accounts receivable, related party, allowance | 12 | 0 |
Debt, current portion, fair value | $ 60,048 | $ 57,918 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 14,656 | 14,656 |
Preferred stock, shares outstanding (in shares) | 14,656 | 14,656 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 250,000,000 | 250,000,000 |
Common stock, shares issued (in shares) | 77,210,681 | 76,564,829 |
Common stock, shares outstanding (in shares) | 77,210,681 | 76,564,829 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Revenue: | ||
Revenues | $ 14,374,000 | $ 17,859,000 |
Cost and operating expenses: | ||
Cost of products sold | 17,707,000 | 5,315,000 |
Research and development | 17,839,000 | 17,825,000 |
Sales, general and administrative | 28,253,000 | 18,100,000 |
Total cost and operating expenses | 63,799,000 | 41,240,000 |
Loss from operations | (49,425,000) | (23,381,000) |
Other income (expense): | ||
Loss on divestiture | (1,778,000) | |
Interest expense | (12,534,000) | (9,978,000) |
Loss from change in fair value of derivative instruments | (2,039,000) | (58,357,000) |
Loss from change in fair value of debt | (48,000) | |
Other income (expense), net | (115,000) | 692,000 |
Total other income (expense), net | (16,818,000) | (69,421,000) |
Loss before income taxes | (66,243,000) | (92,802,000) |
Provision for income taxes | ||
Net loss attributable to Amyris, Inc. | (66,243,000) | (92,802,000) |
Less: losses allocated to participating securities | 2,430,000 | 7,504,000 |
Net loss attributable to Amyris, Inc. common stockholders | $ (63,813,000) | $ (85,298,000) |
Loss per share attributable to common stockholders, basic and diluted (in dollars per share) | $ (0.82) | $ (1.67) |
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares) | 77,512,059 | 51,200,922 |
Product [Member] | ||
Revenue: | ||
Revenues | $ 11,884,000 | $ 5,195,000 |
Licenses and Royalties [Member] | ||
Revenue: | ||
Revenues | 118,000 | 7,955,000 |
Grants and Collaborations [Member] | ||
Revenue: | ||
Revenues | $ 2,372,000 | $ 4,709,000 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Revenues, related party | $ 18 | $ 8,803 |
Product [Member] | ||
Revenues, related party | 2 | 151 |
Licenses and Royalties [Member] | ||
Revenues, related party | (380) | 7,918 |
Grants and Collaborations [Member] | ||
Revenues, related party | $ 396 | $ 734 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Comprehensive loss: | ||
Net loss attributable to Amyris, Inc. | $ (66,243) | $ (92,802) |
Foreign currency translation adjustment | 964 | (137) |
Comprehensive loss attributable to Amyris, Inc. | $ (65,279) | $ (92,939) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) - USD ($) $ in Thousands | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Mezzanine Equity, Common Stock [Member] | Total |
Balance (in shares) at Dec. 31, 2017 | 22,171 | 45,637,433 | ||||||
Balance at Dec. 31, 2017 | $ 5 | $ 1,114,546 | $ (42,156) | $ (1,290,420) | $ 937 | $ 5,000 | $ (217,088) | |
Cumulative effect of change in accounting principle (Accounting Standards Update 2014-09 [Member]) at Dec. 31, 2017 | (803) | (803) | ||||||
Issuance of common stock upon exercise of warrants (in shares) | 162,392 | |||||||
Issuance of common stock upon exercise of warrants | 835 | 835 | ||||||
Issuance of common stock upon exercise of stock options (in shares) | 7,004 | |||||||
Issuance of common stock upon exercise of stock options | 81 | 81 | ||||||
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares) | 30,489 | |||||||
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock | (66) | (66) | ||||||
Stock-based compensation | 1,278 | 1,278 | ||||||
Foreign currency translation adjustment | (137) | (137) | ||||||
Net loss | (92,802) | (92,802) | ||||||
Issuance for private placement, net (in shares) | 13,529 | |||||||
Issuance for private placement, net | 92 | 92 | ||||||
Other | 93 | 93 | ||||||
Balance (in shares) at Mar. 31, 2018 | 22,171 | 45,850,847 | ||||||
Balance at Mar. 31, 2018 | $ 5 | 1,116,859 | (42,293) | (1,384,025) | 937 | 5,000 | $ (308,517) | |
Balance (in shares) at Dec. 31, 2018 | 14,656 | 76,564,829 | 76,564,829 | |||||
Balance at Dec. 31, 2018 | $ 8 | 1,346,996 | (43,343) | (1,521,417) | 937 | 5,000 | $ (216,819) | |
Cumulative effect of change in accounting principle (Accounting Standards Update 2017-11 [Member]) at Dec. 31, 2018 | 32,512 | 8,531 | $ 41,043 | |||||
Issuance of common stock upon exercise of warrants (in shares) | 450,568 | 479,751 | ||||||
Issuance of common stock upon exercise of warrants | 1 | $ 1 | ||||||
Issuance of common stock upon exercise of stock options (in shares) | 3,612 | 3,612 | ||||||
Issuance of common stock upon exercise of stock options | 13 | $ 13 | ||||||
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares) | 191,672 | |||||||
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock | (9) | (9) | ||||||
Stock-based compensation | 3,452 | 3,452 | ||||||
Fair value of bifurcated embedded conversion feature in connection with debt modification | 398 | 398 | ||||||
Foreign currency translation adjustment | 964 | 964 | ||||||
Net loss | (66,243) | (66,243) | ||||||
Balance (in shares) at Mar. 31, 2019 | 14,656 | 77,210,681 | ||||||
Balance at Mar. 31, 2019 | $ 8 | $ 1,383,363 | $ (42,379) | $ (1,579,129) | $ 937 | $ 5,000 | $ (237,200) |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Operating activities | |||
Net loss | $ (66,243,000) | $ (92,802,000) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Amortization of debt discount | 4,628,000 | 4,789,000 | |
Stock-based compensation | 3,452,000 | 1,278,000 | |
Loss from change in fair value of debt | 48,000 | $ (2,082,000) | |
Loss from change in fair value of derivative liabilities | 2,039,000 | 58,357,000 | |
Amortization of right-of-use assets under operating leases | 2,826,000 | ||
Depreciation and amortization | 848,000 | 1,561,000 | |
Write-down of property, plant and equipment | 438,000 | ||
Loss on disposal of property, plant and equipment | 1,000 | 1,035,000 | |
(Gain) loss on foreign currency exchange rates | (108,000) | 243,000 | |
Changes in assets and liabilities: | |||
Accounts receivable | 5,048,000 | 74,000 | |
Accounts receivable, unbilled - related party | 8,021,000 | 93,000 | |
Inventories | 1,196,000 | 420,000 | |
Deferred cost of products sold | (7,173,000) | ||
Prepaid expenses and other assets | 1,766,000 | 6,747,000 | |
Accounts payable | 1,834,000 | (108,000) | |
Accrued and other liabilities | 6,245,000 | (11,120,000) | |
Lease liabilities | (4,036,000) | ||
Contract liabilities | 108,000 | 4,264,000 | |
Net cash used in operating activities | (36,980,000) | (25,169,000) | |
Investing activities | |||
Purchases of property, plant and equipment | (3,046,000) | (1,584,000) | |
Net cash used in investing activities | (3,046,000) | (1,584,000) | |
Financing activities | |||
Proceeds from issuance of debt, net of issuance costs | 484,000 | ||
Proceeds from exercises of common stock options | 13,000 | 81,000 | |
Proceeds from exercises of warrants | 1,000 | 133,000 | |
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units | (9,000) | (66,000) | |
Principal payments on financing leases | (134,000) | (400,000) | |
Principal payments on debt | (577,000) | (6,534,000) | |
Proceeds from issuance of common stock in private placements, net of issuance costs | 92,000 | ||
Net cash used in financing activities | (222,000) | (6,694,000) | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (70,000) | (68,000) | |
Net decrease in cash, cash equivalents and restricted cash | (40,318,000) | (33,515,000) | |
Cash, cash equivalents and restricted cash at beginning of period | 47,054,000 | 61,012,000 | 61,012,000 |
Cash, cash equivalents and restricted cash at end of the period | 6,736,000 | 27,497,000 | 47,054,000 |
Cash and cash equivalents | 5,153,000 | 24,084,000 | 45,353,000 |
Restricted cash, current | 623,000 | 2,454,000 | 741,000 |
Restricted cash, noncurrent | 960,000 | 959,000 | $ 960,000 |
Supplemental disclosures of cash flow information: | |||
Cash paid for interest | 3,099,000 | 1,815,000 | |
Supplemental disclosures of non-cash investing and financing activities: | |||
Right-of-use assets under operating leases recorded upon adoption of ASC 842 (Note 2) | 29,713,000 | ||
Lease liabilities recorded upon adoption of ASC 842 (Note 2) | 33,552,000 | ||
Cumulative effect of change in accounting principle for ASU 2017-11 (Note 2) | 41,043,000 | ||
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable | 605,000 | 264,000 | |
Acquisition of right-of-use assets under operating leases | 758,000 | ||
Right-of-use assets amortization capitalized into inventory | 1,800,000 | ||
Accrued interest added to debt principal | 448,000 | 1,211,000 | |
Fair value of warrants recorded as debt discount in connection with debt modification | 398,000 | ||
Financing of equipment | $ 91,000 |
Note 1 - Basis of Presentation
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 1. Amyris, Inc. (Amyris or the Company) is a leading industrial biotechnology company that applies its technology platform to engineer, manufacture and sell high performance, natural, sustainably-sourced products into the Health & Wellness, Clean Beauty, and Flavor & Fragrance markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company has successfully used its technology to develop and produce several distinct molecules at commercial volumes. The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10 December 31, 2018 2018 10 December 31, 2018 10 10 X. not not Going Concern The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 March 31, 2019, $199.4 $119.5 December 31, 2018 $1.6 As of March 31, 2019, $13.5 $215.8 $153.8 March 31, 2019, 12, March 31, 2020 $179.8 $23.5 Cash and cash equivalents of $5.2 March 31, 2019 not March 31, 2020. one not twelve March 31, 2020 December 31, 2018, may may not On September 16, 2019, $63.6 The Company does not not no no not not Significant Accounting Policies Note 1, 2018 10 no three March 31, 2019, January 1, 2019: • 842 842 Leases; • 2017 11, Earnings Per Share (Topic 260 480 815 Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company generally does not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 2018 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely amount method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Contract liability arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not For descriptions of the Company's other significant accounting policies, see the 2018 10 Accounting Standards or Updates Recently Adopted In the three March 31, 2019, Leases February 2016, No. 2016 02, Leases (Topic 842 July 2018, 2018 11, Leases (Topic 842 842 The Company adopted this standard on January 1, 2019 1 2 3 not not not not not 12 not The adoption of this standard had the effect of increasing assets and liabilities on the condensed consolidated balance sheet by $25.7 not 1 2 Upon adoption, the Company recognized operating lease liabilities of $33.6 $29.7 Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019, 2017 11 $32.5 $8.5 $41.0 Recent Accounting Standards or Updates Not Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Collaborative Revenue Arrangements November 2018, 2018 18, Clarifying the Interaction between Topic 808 606 606, two first 2020 not Credit Losses June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 2016 13 first 2020. not Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may |
Note 2 - Balance Sheet Details
Note 2 - Balance Sheet Details | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 2. Inventories (In thousands) March 31, 2019 December 31, 2018 Raw materials $ 2,451 $ 3,901 Work-in-process 238 539 Finished goods 5,797 5,253 Inventories $ 8,486 $ 9,693 Deferred cost of products sold - related party (In thousands) March 31, 2019 December 31, 2018 Deferred cost of products sold - related party $ 1,489 $ 489 Deferred cost of products sold, noncurrent - related party 9,001 2,828 Total $ 10,490 $ 3,317 In November 2018, 1 2022. 10, 8 2018 10 November 2018 $24.4 $3.3 December 31, 2018. three March 31, 2019, $7.3 $13.8 five December 2018, March 31, 2019. Prepaid expenses and other current assets (In thousands) March 31, 2019 December 31, 2018 Prepayments, advances and deposits $ 3,310 $ 5,644 Recoverable taxes from Brazilian government entities 956 631 Other 3,949 4,291 Total prepaid expenses and other current assets $ 8,215 $ 10,566 Property, Plant and Equipment, Net (In thousands) March 31, 2019 December 31, 2018 Machinery and equipment $ 45,874 $ 43,713 Leasehold improvements 39,951 39,922 Computers and software 10,138 9,987 Furniture and office equipment, vehicles and land 3,279 3,016 Construction in progress 1,460 1,749 Total property, plant and equipment, gross 100,702 98,387 Less: accumulated depreciation and amortization (79,144 ) (78,631 ) Property, plant and equipment, net $ 21,558 $ 19,756 During the three March 31, 2019 2018, $0.2 $0.8 Depreciation and amortization expense, including amortization of assets under financing leases, was $0.8 $1.6 three March 31, 2019 2018, Leases Operating Leases The Company has entered into operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 5 one 1 5 March 31, 2019 March 31, 2019 $29.7 $33.6 January 1, 2019. January 1, 2019 March 31, 2019, $27.6 $29.7 three March 31, 2019, $2.8 $1.8 Because the rate implicit in each lease is not may Information related to the Company's right-of-use assets and related lease liabilities were as follows: Amounts in thousands Three Months Ended March 31, 2019 Cash paid for operating lease liabilities $ 5,305 Right-of-use assets obtained in exchange for new operating lease obligations (1) $ 30,472 Weighted-average remaining lease term (in years) 2.7 Weighted-average discount rate 18.0 % ( 1 $29.7 January 1, 2019 $0.8 first 2019. Financing Leases The Company has entered into financing leases primarily for laboratory and computer equipment. Assets purchased under financing leases are included in "Property, plant and equipment, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Property, plant and equipment, net included $5.3 $5.0 March 31, 2019 December 31, 2018, $2.5 $2.3 March 31, 2019 December 31, 2018, Maturities of Financing and Operating Leases Maturities of lease liabilities as of March 31, 2019 Years ending December 31: Financing Leases Operating Total Leases 2019 (remaining nine months) $ 368 $ 12,755 $ 13,123 2020 199 9,109 9,308 2021 1 7,226 7,227 2022 — 7,398 7,398 2023 — 3,034 3,034 Thereafter — — — Total lease payments 568 39,522 40,090 Less: amount representing interest (23 ) (9,793 ) (9,816 ) Total lease liability $ 545 $ 29,729 $ 30,274 Current lease liability $ 452 $ 10,972 $ 11,424 Noncurrent lease liability 93 18,757 18,850 Total lease liability $ 545 $ 29,729 $ 30,274 Other Assets (In thousands) March 31, 2019 December 31, 2018 Contingent consideration $ 4,286 $ 4,286 Deposits 145 2,465 Other 1,117 1,207 Other assets $ 5,548 $ 7,958 Accrued and Other Current Liabilities (In thousands) March 31, 2019 December 31, 2018 DSM manufacturing capacity fee $ 7,250 $ — Contract termination fees 5,337 6,247 Accrued interest 7,094 3,853 Payroll and related expenses 5,285 9,220 Asset retirement obligation 3,111 3,063 Tax-related liabilities 2,589 2,139 Professional services 1,871 1,173 Other 1,054 3,284 Total accrued and other current liabilities $ 33,591 $ 28,979 Other noncurrent liabilities (In thousands) March 31, 2019 December 31, 2018 Contract termination fees, net of current portion $ 8,207 $ 7,715 Liability for unrecognized tax benefit 6,582 6,582 Contract liability, net of current portion (Note 9) 1,449 1,587 Deferred rent, net of current portion (1) — 6,440 Other 682 868 Total other noncurrent liabilities $ 16,920 $ 23,192 ( 1 December 31, 2018 January 1, 2019 842, |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurement | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Financial Instruments Disclosure [Text Block] | 3. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following tables summarize assets and liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy: (In thousands) March 31, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities 6% Convertible Notes Due 2021 $ — $ — $ 60,048 $ 60,048 $ — $ — $ 57,918 $ 57,918 Freestanding derivative instruments in connection with the issuance of equity instruments — — 3,798 3,798 — — 42,796 42,796 Total liabilities measured and recorded at fair value $ — $ — $ 63,846 $ 63,846 $ — $ — $ 100,714 $ 100,714 There were no 6% 2021 The Company issued $60.0 6% 2021 December 10, 2018 March 31, 2019, $60.0 $60.0 23.8% 45% 50% 50% 5% 4, three March 31, 2019, $2.1 6% 2021, In thousands Fair value at December 31, 2018 $ 57,918 Change in fair value 2,130 Fair value at March 31, 2019 $ 60,048 Derivative Liabilities Recognized in Connection with the Issuance of Debt and Equity Instruments The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt and equity instruments, measured at fair value using significant unobservable inputs (Level 3 (In thousands) Equity-related Derivative Liability Debt-related Derivative Liability Total Derivative Liability Balance at December 31, 2018 $ 41,272 $ 1,524 $ 42,796 Derecognition upon adoption of ASU 2017-11 (39,513 ) (1,524 ) (41,037 ) Change in fair value of derivative liabilities 2,039 — 2,039 Balance at March 31, 2019 $ 3,798 $ — $ 3,798 As of March 31, 2019, November 2018 10, 8 2018 10 Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes are recorded at carrying value (except for the 6% 2021, 2 3 March 31, 2019, 6% $155.8 March 31, 2019 $155.8 third |
Note 4 - Debt
Note 4 - Debt | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 4. Net carrying amounts of debt are as follows: March 31, 2019 December 31, 2018 (In thousands) Principal Unamortized Debt (Discount) Premium Change in Fair Value Net Balance Principal Unamortized Debt (Discount) Premium Change in Fair Value Net Balance Convertible notes payable 6% convertible notes due 2021 $ 60,000 $ — $ 48 $ 60,048 $ 60,000 $ — $ (2,082 ) $ 57,918 2015 Rule 144A convertible notes 37,887 (358 ) — 37,529 37,887 (2,413 ) — 35,474 2014 Rule 144A convertible notes 24,004 (289 ) — 23,715 24,004 (867 ) — 23,137 August 2013 financing convertible note 4,863 (596 ) — 4,267 4,415 (70 ) — 4,345 126,754 (1,243 ) 48 125,559 126,306 (3,350 ) (2,082 ) 120,874 Related party convertible notes payable 2014 Rule 144A convertible notes 24,705 (346 ) — 24,359 24,705 (1,038 ) — 23,667 Loans payable and credit facilities GACP secured term loan facility 36,000 (1,208 ) — 34,792 36,000 (1,349 ) — 34,651 Ginkgo note 12,000 (3,832 ) — 8,168 12,000 (4,047 ) — 7,953 Other loans payable 4,813 (1,011 ) — 3,802 4,910 (1,047 ) — 3,863 52,813 (6,051 ) — 46,762 52,910 (6,443 ) — 46,467 Related party loans payable DSM note 25,000 (5,853 ) — 19,147 25,000 (6,311 ) — 18,689 Total debt $ 229,272 $ (13,493 ) $ 48 215,827 $ 228,921 $ (17,142 ) $ (2,082 ) 209,697 Less: current portion (153,752 ) (147,677 ) Long-term debt, net of current portion $ 62,075 $ 62,020 The 6% 2021 March 31, 2019 December 31, 2018 March 31, 2019 March 31, 2019 December 31, 2018 12, On January 14, 2019, August 2013 January 15, 2019 July 15, 2019 July 15, 2019, $0.6 July 15, 2019, October 13, 2019 1.75% July 16, 2019 12, Future Minimum Payments Future minimum payments under the Company's debt agreements as of March 31, 2019 (In thousands) Convertible Loans Related Related Total 2019 (remaining nine months) $ 139,303 $ 9,689 $ 25,618 $ 1,875 $ 176,485 2020 — 10,113 — 2,500 12,613 2021 — 34,776 — 28,146 62,922 2022 — 13,450 — — 13,450 2023 — 399 — — 399 Thereafter — 2,268 — — 2,268 Total future minimum payments 139,303 70,695 25,618 32,521 268,137 Less: amount representing interest (12,303 ) (17,883 ) (913 ) (7,521 ) (38,620 ) Less: future conversion of accrued interest to principal (245 ) — — — (245 ) Present value of minimum debt payments 126,755 52,812 24,705 25,000 229,272 Less: current portion of debt principal (126,755 ) (4,513 ) (24,705 ) — (155,973 ) Noncurrent portion of debt principal $ — $ 48,299 $ — $ 25,000 $ 73,299 |
Note 5 - Mezzanine Equity
Note 5 - Mezzanine Equity | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Mezzanine Equity Disclosure [Text Block] | 5. Mezzanine equity is comprised of the following: (In thousands) March 31, 2019 December 31, 2018 Contingently redeemable common stock $ 5,000 $ 5,000 Mezzanine equity at March 31, 2019 December 31, 2018 May 10, 2016 not third $17.10 10%. As of March 31, 2019, $0.6 |
Note 6 - Stockholders' Deficit
Note 6 - Stockholders' Deficit | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 6. Warrants In connection with various debt and equity transactions (see Note 5, 7, 8 2018 10 three March 31, 2019: Transaction Number Outstanding as of December 31, 2018 Additional Warrants Issued Exercises Number Outstanding as of March 31, 2019 August 2018 warrant exercise agreements 12,097,164 — — 12,097,164 May 2017 cash and dilution warrants 6,292,798 — — 6,292,798 August 2017 cash and dilution warrants 3,968,116 — — 3,968,116 April 2018 warrant exercise agreements 3,616,174 — — 3,616,174 July 2015 related party debt exchange 663,228 — (471,204 ) 192,024 February 2016 related party private placement 171,429 — — 171,429 July 2015 private placement 81,197 — (8,547 ) 72,650 Other 1,406 — — 1,406 26,891,512 — (479,751 ) 26,411,761 For the three March 31, 2019, 479,751 $0.01 no 450,568 |
Note 7 - Loss Per Share
Note 7 - Loss Per Share | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 7. For the three March 31, 2019 March 31, 2018, The Company follows the two two two The following table presents the calculation of basic and diluted loss per share: Three Months Ended March 31, (In thousands, except shares and per share amounts) 2019 2018 Numerator: Net loss attributable to Amyris, Inc. $ (66,243 ) $ (92,802 ) Less: losses allocated to participating securities 2,430 7,504 Net loss attributable to Amyris, Inc. common stockholders $ (63,813 ) $ (85,298 ) Denominator: Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted 77,512,059 51,200,922 Loss per share attributable to common stockholders, basic and diluted $ (0.82 ) $ (1.67 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive: Three Months Ended March 31, 2019 2018 Period-end stock options to purchase common stock 5,427,384 1,365,447 Convertible promissory notes (1) 12,699,607 8,347,364 Period-end common stock warrants 26,411,761 29,759,452 Period-end restricted stock units 5,493,579 706,697 Period-end preferred stock 2,955,732 4,504,212 Total potentially dilutive securities excluded from computation of diluted loss per share 52,988,063 44,683,172 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Contingencies Disclosure [Text Block] | 8. Contingencies The Company has levied indirect taxes on sugarcane-based biodiesel sales that took place several years ago by Amyris Brasil Ltda. (see Note 12, 8 2018 10 On April 3, 2019, March 15, 2018 March 19, 2019. June 21, 2019 October 1, 2019, two No. 4:19 03621 No. 4:19 06230 not The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not not |
Note 9 - Revenue Recognition an
Note 9 - Revenue Recognition and Contract Assets and Liabilities | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 9. Disaggregation of Revenue The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer: Three Months Ended March 31, (In thousands) 2019 2018 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 7,073 $ — $ 493 $ 7,566 $ 1,962 $ — $ 1,209 $ 3,171 Europe 2,854 118 1,629 4,601 2,434 7,955 3,500 13,889 Asia 1,718 — 250 1,968 678 — — 678 South America 220 — — 220 21 — — 21 Other 19 — — 19 100 — — 100 $ 11,884 $ 118 $ 2,372 $ 14,374 $ 5,195 $ 7,955 $ 4,709 $ 17,859 Significant Revenue Agreements During the Three Months Ended March 31, 2019 In connection with significant revenue agreements, the Company recognized the following revenues for the three March 31, 2019 2018 : Three Months Ended March 31, (In thousands) 2019 2018 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total Firmenich $ 1,891 $ 498 $ 728 $ 3,117 $ 207 $ 37 $ 1,267 $ 1,511 Givaudan 1,575 — — 1,575 1,076 — 1,500 2,576 American Sugar Refining 1,494 — — 1,494 — — — — DSM - related party 2 (380 ) 396 18 — 7,918 734 8,652 Subtotal revenue from significant revenue agreements 4,962 118 1,124 6,204 1,283 7,955 3,501 12,739 Revenue from all other customers 6,922 — 1,248 8,170 3,912 — 1,208 5,120 Total revenue from all customers $ 11,884 $ 118 $ 2,372 $ 14,374 $ 5,195 $ 7,955 $ 4,709 $ 17,859 Contract Assets and Liabilities When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade accounts receivable are recorded at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company for sale of goods or the performance of services. Contract Balances The following table provides information about accounts receivable and contract liabilities from contracts with customers: (In thousands) March 31, 2019 December 31, 2018 Accounts receivable, net $ 10,968 $ 16,003 Accounts receivable - related party, net $ 1,334 $ 1,349 Accounts receivable, unbilled - related party $ — $ 8,021 Accounts receivable, unbilled, noncurrent - related party $ 1,203 $ 1,203 Contract liabilities $ 8,333 $ 8,236 Contract liabilities, noncurrent (1) $ 1,449 $ 1,587 ( 1 March 31, 2019 December 31, 2018, Unbilled receivables at the end of the period relate to the Company’s right to consideration from DSM for performance fees. The Company’s right to cash receipt for these minimum royalty amounts occurs on or before December 31, 2019. December 31, 2018 March 31, 2019, $8.0 $8.0 December 31, 2019 $0.6 $7.4 $0.4 $0.2 Remaining Performance Obligations The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2019. (In thousands) As of March 31, 2019 Remaining 2019 $ 23,920 2020 38,508 2021 31,172 2022 and thereafter — Total from all customers $ 93,600 In accordance with the disclosure provisions of ASC 606, one $17.6 |
Note 10 - Related Party Transac
Note 10 - Related Party Transactions | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 10. Related Party Debt See Note 4, March 31, 2019 December 31, 2018. Related Party Accounts Receivable and Unbilled Receivables Related party accounts receivable and unbilled receivables as of March 31, 2019 December 31, 2018 (In thousands) March 31, 2019 December 31, 2018 Accounts receivable: DSM $ 1,334 $ 1,071 Novvi — 188 Total — 90 $ 1,334 $ 1,349 Accounts receivable, unbilled, current: DSM $ — $ 8,021 Accounts receivable, unbilled, noncurrent: DSM $ 1,203 $ 1,203 Related Party Joint Ventures The Company holds a 50% |
Note 11 - Stock-based Compensat
Note 11 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 11. The Company’s stock option activity and related information for the three March 31, 2019 Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2018 5,390,270 $ 11.55 8.5 $ 29 Granted 104,452 $ 4.73 Exercised (3,612 ) $ 3.68 Forfeited or expired (63,726 ) $ 14.27 Outstanding - March 31, 2019 5,427,384 $ 11.39 8.3 $ — Vested or expected to vest after March 31, 2019 4,874,155 $ 12.10 8.3 $ — Exercisable at March 31, 2019 977,466 $ 39.20 5.8 $ — The Company’s restricted stock units (RSUs) activity and related information for the three March 31, 2019 Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2018 5,294,803 $ 5.50 1.7 Awarded 493,790 $ 4.65 RSUs released (192,795 ) $ 6.55 RSUs forfeited (102,219 ) $ 5.61 Outstanding - March 31, 2019 5,493,579 $ 5.38 1.5 Vested or expected to vest after March 31, 2019 5,153,107 $ 5.39 1.5 Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three March 31, 2019 2018 Three Months Ended March 31, (In thousands) 2019 2018 Research and development $ 663 $ 363 Sales, general and administrative 2,789 915 Total stock-based compensation expense $ 3,452 $ 1,278 As of March 31, 2019, $31.1 3.0 Evergreen Shares for 2010 2010 In February 2019, 2010 2010 3,828,241 5.0% 76,564,829 December 31, 2018. January 1, 2019. 383,824 0.5% 76,564,829 December 31, 2018. January 1, 2019. |
Note 12 - Subsequent Events
Note 12 - Subsequent Events | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 12. Cannabinoid Agreement On May 2, 2019, March 18, 2019 $300 $300 20 third 2014 144A 2015 144A 4, May 2, 2019, 4, LSA Amendments, Assignment and Waivers On April 4, 2019, 4, December 31, 2018, July 1, 2021, ( $15 On April 4, 2019, December 31, 2018 April 8, 2019, $0.8 On April 15, 2019, five $2.5 April 16, 2019. On August 14, 2019, No. 5 July 1, 2021 July 1, 2022, ( x 4.75% 9% 12% December 16, 2019, ( December 16, 2019, ( April 8, 2019, June 11, 2019, July 10, 2019 July 26, 2019 ( $32.5 $71.0 August 14, 2019 1,438,829 $2.87 two may not 19.99% 2019 Foris Credit Agreements On April 8, 2019, $8.0 April April 8, 2019 $8.0 April April October 14, 2019. April April no $1.0 April April April $0.5 April July 15, 2019. April 4, 12, On June 11, 2019, $8.5 June 11, 2019 $8.5 June June 12.5% June 11, 2019, June August 28, 2019; May 2017 August 2017 6, June On July 10, 2019, $16.0 July $8.0 July 10, 2019 $8.0 July 26, 2019 $8.0 July July 12.5% July December 31, 2019. July August 17, 2018 ( 6, $7.52 $2.87 The Company may April April June July 100% June July On August 14, 2019, April June July On August 28, 2019, $19.0 August August 28, 2019 $19.0 August August 12% August 28, 2019, March 31, June 30, September 30 December 31, December 31, 2019, January 1, 2023. may August 100% August 28, 2019 August April 26, 2019 $5.12 $3.90 May 14, 2019 $4.56 $3.90 6, In connection with the entry into the August August 14, 2019 4,871,795 $3.90 two 4 2 1933, not six not may not 19.99% 2019 Private Placements On April 16, 2019, 6,732,369 $2.87 5,424,804 $2.87 two 4 2 $20.0 On April 26, 2019, 2,832,440 $5.12 3,983,230 $5.12 two 2,043,781 $4.02 1,635,025 $5.02 two 4 2 $23.2 August 28, 2019, August April 26, 2019 $5.12 $3.90 On April 29, 2019, 913,529 $4.76 1,212,787 $4.76 two 323,382 $4.02 258,704 $5.02 two 4 2 $5.8 On May 3, 2019, 1,243,781 $4.02 995,024 $5.02 two 4 2 $5 The exercise price of the warrants issued in the foregoing private placements is subject to standard adjustments but does not six not not not 19.99% DSM Agreements On April 16, 2019, 9, $57.0 $29.1 $27.9 2015 144A 4, In addition, on April 16, 2019 9, December 2017 13, 8 2018 10 2021, no On September 17, 2019, “2019 $8.0 $3.0 $3.0 $2.0 September 17, 2019, first $3.0 2019 $3.0 September 19, 2019, second $3.0 2019 $3.0 September 23, 2019, $2.0 2019 $1.5 $2.0 2019 August 7, 2022, ( 12.5% January 1, April 1, July 1 October 1, January 1, 2020, first may 2019 100% 2019 May 11, 2017 August 7, 2017 ( 7, $50.0 one June 30, 2020. Raizen Joint Venture Agreement On May 10, 2019, not December 31, 2019, may not Upon the closing of the joint venture, each party will make an initial capital contribution to the joint venture of 2,500,000 R$2,500,000 50% 50% 60 U.S.$9,000,000 U.S.$3,000,000. six 10 After the formation of the joint venture, the parties will not not third seventh 2015 2014 144A On April 16, 2019, $37.9 2015 144A On May 10, 2019, $13.5 2014 144A 4, May 15, 2019, 3,479,008 1,391,603 $5.02 two 3 9 On May 14, 2019, $5.0 2014 144A May 15, 2019, 1,122,460 352,638 $4.56 two 3 9 August 28, 2019, August May 14, 2019 $4.56 $3.90 On May 15, 2019, $10.0 2014 144A 2,500,000 3 9 On May 15, 2019, $9.7 2014 144A June 14, 2019, 3 9 June 14, 2019, June 14, 2019 July 18, 2019. July 18, 2019, July 18, 2019 August 28, 2019 10.50% July 18, 2019. The exercise price of the warrants issued in the foregoing exchanges is subject to standard adjustments but does not six not 2019 may not 4.99% 6% 2021 On May 15, 2019 June 24, 2019, $53.3 $4.7 6% 2021 4, 6% 2021, 2,000,000 181,818 $5.12 two 3 9 6% 2021 July 22, 2019, July 22, 2019 July 29, 2019, 125% not six not may not may not 4.99% On July 24, 2019, $53.3 6% 2021 2,000,000 May 15, 2019, $68.3 2,000,000 $2.87 two May 15, 2019 ( 3 9 May 15, 2019, $68.3 25% July 1, 2019 $6.4 not 18% July 22, 2019 September 16, 2019, ( first October 1, 2019, ( $3.2 August 2, 2019 August 22, 2019, September 16, 2019, 8 September 16, 2019, $2.87 On July 26, 2019, one 6% 2021, $4.7 June 24, 2019, 125% July 30, 2019 August 30, 2019. August 30, 2019. On September 16, 2019, $63.6 The Company does not not no no not not Exchange of August 2013 On July 8, 2019, August 2013 4, 1,767,632 1,080,000 3 9 not six not may not 4.99% Nikko Loan Agreement On July 29, 2019, $5.0 $3.0 $2.0 10, July 30, 2019, first $3.0 $2.8 $0.2 August 8, 2019, $2.0 $1.9 $0.1 December 18, 2020, ( 5% first 12.8% Aprinnova Working Capital Loan Effective July 31, 2019, 5, 2018 10 August 1, 2019 August 1, 2020. Naxyris Loan and Security Agreement On August 14, 2019, $10,435,000 August 14, 2019. Loans under the Naxyris Loan Facility have a maturity date of July 1, 2022 12% 25 August 14, 2019 December 1, 2019 December 15, 2019. The obligations of the Company under the Naxyris Loan Facility are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris Ventures subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement (as defined above). Mandatory prepayments of the outstanding amounts under the Naxyris Loan Facility will be required upon the occurrence of certain events, including asset sales, a change in control, and the incurrence of additional indebtedness, subject to certain exceptions and reinvestment rights. Outstanding amounts under the Naxyris Loan Facility must also be prepaid to the extent that the borrowing base exceeds the outstanding principal amount of the loans under the Naxyris Loan Facility. In addition, the Company may one 6% three not The affirmative and negative covenants in the Naxyris Loan Agreement relate to, among other items: (i) payment of taxes; (ii) financial reporting; (iii) maintenance of insurance; and (iv) limitations on indebtedness, liens, mergers, consolidations and acquisitions, transfers of assets, dividends and other distributions in respect of capital stock, investments, loans and advances, and corporate changes. The Naxyris Loan Agreement also contains financial covenants, including covenants related to minimum revenue, liquidity, and asset coverage. September 2019 On September 10, 2019, $12.5 September 10, 2019 $12.5 12% September 10, 2019, March 31, June 30, September 30 December 31, December 31, 2019, January 1, 2023. may 100% In connection with the entry into the Investor Credit Agreements, on September 10, 2019, 3,205,128 $3.90 two 4 2 not six not no may 9.99% 60 120 no 144 not 10%, 5% 90 $3.31 $3.90 In connection with the entry into the Investor Credit Agreements and the issuance of the warrants, on September 10, 2019, no 6.99% third Ginkgo Note Amendment On September 29, 2019, November 2017 5, 10, 8 2018 10 November 2017 10.5% 12% October 1, 2019 $1.3 December 15, 2019 March 31, 2020. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Liquidity [Policy Text Block] | Going Concern The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 March 31, 2019, $199.4 $119.5 December 31, 2018 $1.6 As of March 31, 2019, $13.5 $215.8 $153.8 March 31, 2019, 12, March 31, 2020 $179.8 $23.5 Cash and cash equivalents of $5.2 March 31, 2019 not March 31, 2020. one not twelve March 31, 2020 December 31, 2018, may may not On September 16, 2019, $63.6 The Company does not not no no not not |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company generally does not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 2018 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely amount method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Contract liability arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not For descriptions of the Company's other significant accounting policies, see the 2018 10 |
New Accounting Pronouncements, Policy [Policy Text Block] | Accounting Standards or Updates Recently Adopted In the three March 31, 2019, Leases February 2016, No. 2016 02, Leases (Topic 842 July 2018, 2018 11, Leases (Topic 842 842 The Company adopted this standard on January 1, 2019 1 2 3 not not not not not 12 not The adoption of this standard had the effect of increasing assets and liabilities on the condensed consolidated balance sheet by $25.7 not 1 2 Upon adoption, the Company recognized operating lease liabilities of $33.6 $29.7 Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019, 2017 11 $32.5 $8.5 $41.0 Recent Accounting Standards or Updates Not Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Collaborative Revenue Arrangements November 2018, 2018 18, Clarifying the Interaction between Topic 808 606 606, two first 2020 not Credit Losses June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 2016 13 first 2020. not |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may |
Note 2 - Balance Sheet Details
Note 2 - Balance Sheet Details (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Raw materials $ 2,451 $ 3,901 Work-in-process 238 539 Finished goods 5,797 5,253 Inventories $ 8,486 $ 9,693 |
Deferred Cost of Products Sold Disclosure [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Deferred cost of products sold - related party $ 1,489 $ 489 Deferred cost of products sold, noncurrent - related party 9,001 2,828 Total $ 10,490 $ 3,317 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Prepayments, advances and deposits $ 3,310 $ 5,644 Recoverable taxes from Brazilian government entities 956 631 Other 3,949 4,291 Total prepaid expenses and other current assets $ 8,215 $ 10,566 |
Property, Plant and Equipment [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Machinery and equipment $ 45,874 $ 43,713 Leasehold improvements 39,951 39,922 Computers and software 10,138 9,987 Furniture and office equipment, vehicles and land 3,279 3,016 Construction in progress 1,460 1,749 Total property, plant and equipment, gross 100,702 98,387 Less: accumulated depreciation and amortization (79,144 ) (78,631 ) Property, plant and equipment, net $ 21,558 $ 19,756 |
Lease, Cost [Table Text Block] | Amounts in thousands Three Months Ended March 31, 2019 Cash paid for operating lease liabilities $ 5,305 Right-of-use assets obtained in exchange for new operating lease obligations (1) $ 30,472 Weighted-average remaining lease term (in years) 2.7 Weighted-average discount rate 18.0 % |
Lessee, Lease Liability, Maturity [Table Text Block] | Years ending December 31: Financing Leases Operating Total Leases 2019 (remaining nine months) $ 368 $ 12,755 $ 13,123 2020 199 9,109 9,308 2021 1 7,226 7,227 2022 — 7,398 7,398 2023 — 3,034 3,034 Thereafter — — — Total lease payments 568 39,522 40,090 Less: amount representing interest (23 ) (9,793 ) (9,816 ) Total lease liability $ 545 $ 29,729 $ 30,274 Current lease liability $ 452 $ 10,972 $ 11,424 Noncurrent lease liability 93 18,757 18,850 Total lease liability $ 545 $ 29,729 $ 30,274 |
Schedule of Other Assets, Noncurrent [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Contingent consideration $ 4,286 $ 4,286 Deposits 145 2,465 Other 1,117 1,207 Other assets $ 5,548 $ 7,958 |
Schedule of Accrued and Other Current Liabilities [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 DSM manufacturing capacity fee $ 7,250 $ — Contract termination fees 5,337 6,247 Accrued interest 7,094 3,853 Payroll and related expenses 5,285 9,220 Asset retirement obligation 3,111 3,063 Tax-related liabilities 2,589 2,139 Professional services 1,871 1,173 Other 1,054 3,284 Total accrued and other current liabilities $ 33,591 $ 28,979 |
Other Noncurrent Liabilities [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Contract termination fees, net of current portion $ 8,207 $ 7,715 Liability for unrecognized tax benefit 6,582 6,582 Contract liability, net of current portion (Note 9) 1,449 1,587 Deferred rent, net of current portion (1) — 6,440 Other 682 868 Total other noncurrent liabilities $ 16,920 $ 23,192 |
Note 3 - Fair Value Measureme_2
Note 3 - Fair Value Measurement (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities 6% Convertible Notes Due 2021 $ — $ — $ 60,048 $ 60,048 $ — $ — $ 57,918 $ 57,918 Freestanding derivative instruments in connection with the issuance of equity instruments — — 3,798 3,798 — — 42,796 42,796 Total liabilities measured and recorded at fair value $ — $ — $ 63,846 $ 63,846 $ — $ — $ 100,714 $ 100,714 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | In thousands Fair value at December 31, 2018 $ 57,918 Change in fair value 2,130 Fair value at March 31, 2019 $ 60,048 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | (In thousands) Equity-related Derivative Liability Debt-related Derivative Liability Total Derivative Liability Balance at December 31, 2018 $ 41,272 $ 1,524 $ 42,796 Derecognition upon adoption of ASU 2017-11 (39,513 ) (1,524 ) (41,037 ) Change in fair value of derivative liabilities 2,039 — 2,039 Balance at March 31, 2019 $ 3,798 $ — $ 3,798 |
Note 4 - Debt (Tables)
Note 4 - Debt (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | March 31, 2019 December 31, 2018 (In thousands) Principal Unamortized Debt (Discount) Premium Change in Fair Value Net Balance Principal Unamortized Debt (Discount) Premium Change in Fair Value Net Balance Convertible notes payable 6% convertible notes due 2021 $ 60,000 $ — $ 48 $ 60,048 $ 60,000 $ — $ (2,082 ) $ 57,918 2015 Rule 144A convertible notes 37,887 (358 ) — 37,529 37,887 (2,413 ) — 35,474 2014 Rule 144A convertible notes 24,004 (289 ) — 23,715 24,004 (867 ) — 23,137 August 2013 financing convertible note 4,863 (596 ) — 4,267 4,415 (70 ) — 4,345 126,754 (1,243 ) 48 125,559 126,306 (3,350 ) (2,082 ) 120,874 Related party convertible notes payable 2014 Rule 144A convertible notes 24,705 (346 ) — 24,359 24,705 (1,038 ) — 23,667 Loans payable and credit facilities GACP secured term loan facility 36,000 (1,208 ) — 34,792 36,000 (1,349 ) — 34,651 Ginkgo note 12,000 (3,832 ) — 8,168 12,000 (4,047 ) — 7,953 Other loans payable 4,813 (1,011 ) — 3,802 4,910 (1,047 ) — 3,863 52,813 (6,051 ) — 46,762 52,910 (6,443 ) — 46,467 Related party loans payable DSM note 25,000 (5,853 ) — 19,147 25,000 (6,311 ) — 18,689 Total debt $ 229,272 $ (13,493 ) $ 48 215,827 $ 228,921 $ (17,142 ) $ (2,082 ) 209,697 Less: current portion (153,752 ) (147,677 ) Long-term debt, net of current portion $ 62,075 $ 62,020 |
Schedule of Long-term Debt Instruments [Table Text Block] | (In thousands) Convertible Loans Related Related Total 2019 (remaining nine months) $ 139,303 $ 9,689 $ 25,618 $ 1,875 $ 176,485 2020 — 10,113 — 2,500 12,613 2021 — 34,776 — 28,146 62,922 2022 — 13,450 — — 13,450 2023 — 399 — — 399 Thereafter — 2,268 — — 2,268 Total future minimum payments 139,303 70,695 25,618 32,521 268,137 Less: amount representing interest (12,303 ) (17,883 ) (913 ) (7,521 ) (38,620 ) Less: future conversion of accrued interest to principal (245 ) — — — (245 ) Present value of minimum debt payments 126,755 52,812 24,705 25,000 229,272 Less: current portion of debt principal (126,755 ) (4,513 ) (24,705 ) — (155,973 ) Noncurrent portion of debt principal $ — $ 48,299 $ — $ 25,000 $ 73,299 |
Note 5 - Mezzanine Equity (Tabl
Note 5 - Mezzanine Equity (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Mezzanine Equity Table [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Contingently redeemable common stock $ 5,000 $ 5,000 |
Note 6 - Stockholders' Deficit
Note 6 - Stockholders' Deficit (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Transaction Number Outstanding as of December 31, 2018 Additional Warrants Issued Exercises Number Outstanding as of March 31, 2019 August 2018 warrant exercise agreements 12,097,164 — — 12,097,164 May 2017 cash and dilution warrants 6,292,798 — — 6,292,798 August 2017 cash and dilution warrants 3,968,116 — — 3,968,116 April 2018 warrant exercise agreements 3,616,174 — — 3,616,174 July 2015 related party debt exchange 663,228 — (471,204 ) 192,024 February 2016 related party private placement 171,429 — — 171,429 July 2015 private placement 81,197 — (8,547 ) 72,650 Other 1,406 — — 1,406 26,891,512 — (479,751 ) 26,411,761 |
Note 7 - Loss Per Share (Tables
Note 7 - Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended March 31, (In thousands, except shares and per share amounts) 2019 2018 Numerator: Net loss attributable to Amyris, Inc. $ (66,243 ) $ (92,802 ) Less: losses allocated to participating securities 2,430 7,504 Net loss attributable to Amyris, Inc. common stockholders $ (63,813 ) $ (85,298 ) Denominator: Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted 77,512,059 51,200,922 Loss per share attributable to common stockholders, basic and diluted $ (0.82 ) $ (1.67 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended March 31, 2019 2018 Period-end stock options to purchase common stock 5,427,384 1,365,447 Convertible promissory notes (1) 12,699,607 8,347,364 Period-end common stock warrants 26,411,761 29,759,452 Period-end restricted stock units 5,493,579 706,697 Period-end preferred stock 2,955,732 4,504,212 Total potentially dilutive securities excluded from computation of diluted loss per share 52,988,063 44,683,172 |
Note 9 - Revenue Recognition _2
Note 9 - Revenue Recognition and Contract Assets and Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three Months Ended March 31, (In thousands) 2019 2018 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 7,073 $ — $ 493 $ 7,566 $ 1,962 $ — $ 1,209 $ 3,171 Europe 2,854 118 1,629 4,601 2,434 7,955 3,500 13,889 Asia 1,718 — 250 1,968 678 — — 678 South America 220 — — 220 21 — — 21 Other 19 — — 19 100 — — 100 $ 11,884 $ 118 $ 2,372 $ 14,374 $ 5,195 $ 7,955 $ 4,709 $ 17,859 |
Revenue in Connection with Significant Revenue Agreement [Table Text Block] | Three Months Ended March 31, (In thousands) 2019 2018 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total Firmenich $ 1,891 $ 498 $ 728 $ 3,117 $ 207 $ 37 $ 1,267 $ 1,511 Givaudan 1,575 — — 1,575 1,076 — 1,500 2,576 American Sugar Refining 1,494 — — 1,494 — — — — DSM - related party 2 (380 ) 396 18 — 7,918 734 8,652 Subtotal revenue from significant revenue agreements 4,962 118 1,124 6,204 1,283 7,955 3,501 12,739 Revenue from all other customers 6,922 — 1,248 8,170 3,912 — 1,208 5,120 Total revenue from all customers $ 11,884 $ 118 $ 2,372 $ 14,374 $ 5,195 $ 7,955 $ 4,709 $ 17,859 |
Contract with Customer, Asset and Liability [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Accounts receivable, net $ 10,968 $ 16,003 Accounts receivable - related party, net $ 1,334 $ 1,349 Accounts receivable, unbilled - related party $ — $ 8,021 Accounts receivable, unbilled, noncurrent - related party $ 1,203 $ 1,203 Contract liabilities $ 8,333 $ 8,236 Contract liabilities, noncurrent (1) $ 1,449 $ 1,587 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] | (In thousands) As of March 31, 2019 Remaining 2019 $ 23,920 2020 38,508 2021 31,172 2022 and thereafter — Total from all customers $ 93,600 |
Note 10 - Related Party Trans_2
Note 10 - Related Party Transactions (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Related Party Accounts Receivables [Table Text Block] | (In thousands) March 31, 2019 December 31, 2018 Accounts receivable: DSM $ 1,334 $ 1,071 Novvi — 188 Total — 90 $ 1,334 $ 1,349 Accounts receivable, unbilled, current: DSM $ — $ 8,021 Accounts receivable, unbilled, noncurrent: DSM $ 1,203 $ 1,203 |
Note 11 - Stock-based Compens_2
Note 11 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block] | Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2018 5,390,270 $ 11.55 8.5 $ 29 Granted 104,452 $ 4.73 Exercised (3,612 ) $ 3.68 Forfeited or expired (63,726 ) $ 14.27 Outstanding - March 31, 2019 5,427,384 $ 11.39 8.3 $ — Vested or expected to vest after March 31, 2019 4,874,155 $ 12.10 8.3 $ — Exercisable at March 31, 2019 977,466 $ 39.20 5.8 $ — |
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] | Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2018 5,294,803 $ 5.50 1.7 Awarded 493,790 $ 4.65 RSUs released (192,795 ) $ 6.55 RSUs forfeited (102,219 ) $ 5.61 Outstanding - March 31, 2019 5,493,579 $ 5.38 1.5 Vested or expected to vest after March 31, 2019 5,153,107 $ 5.39 1.5 |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended March 31, (In thousands) 2019 2018 Research and development $ 663 $ 363 Sales, general and administrative 2,789 915 Total stock-based compensation expense $ 3,452 $ 1,278 |
Note 1 - Basis of Presentatio_2
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) | Jan. 01, 2019 | Sep. 16, 2019 | Mar. 31, 2019 | Dec. 31, 2018 |
Working Capital | $ (199,400,000) | $ (119,500,000) | ||
Retained Earnings (Accumulated Deficit), Ending Balance | (1,579,129,000) | (1,521,417,000) | ||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total | 13,500,000 | |||
Long-term Debt, Total | 215,827,000 | 209,697,000 | ||
Long-term Debt, Current Maturities, Including Due to Related Parties | 153,752,000 | 147,677,000 | ||
Long-term Debt, Current Maturities Due Within 60 Days, Including Due to Related Parties | 179,800,000 | |||
Long-term Debt, Current Maturities Due Within 60 Days, Including Due to Related Parties, Anticipated Interest Portion | 23,500,000 | |||
Cash, Cash Equivalents, and Short-term Investments, Total | 5,200,000 | |||
Assets, Total | 105,147,000 | 127,925,000 | ||
Operating Lease, Liability, Total | 29,729,000 | |||
Operating Lease, Right-of-Use Asset | $ 800,000 | 27,645,000 | ||
Liabilities, Total | $ 337,347,000 | $ 339,744,000 | ||
Accounting Standards Update 2016-02 [Member] | ||||
Assets, Total | 25,700,000 | |||
Operating Lease, Liability, Total | 33,600,000 | |||
Operating Lease, Right-of-Use Asset | 29,700,000 | |||
Liabilities, Total | 24,900,000 | |||
Accounting Standards Update 2017-11 [Member] | ||||
Retained Earnings (Accumulated Deficit), Ending Balance | (8,500,000) | |||
Additional Paid in Capital, Ending Balance | 32,500,000 | |||
Increase (Decrease) in Derivative Liabilities | $ (41,000,000) | |||
Convertible Senior Notes, 6.0%, Due in 2021, Second Exchange [Member] | Subsequent Event [Member] | ||||
Debt Instrument, Debt Default, Amount | $ 63,600,000 |
Note 2 - Balance Sheet Detail_2
Note 2 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Jan. 01, 2019 | Dec. 31, 2018 | |
Manufacturing Capacity Reservation Fee Current | $ 7,250 | |||
Deferred Cost of Products Sold, Related Party | 10,490 | 3,317 | ||
Capitalized Computer Software, Additions | 200 | |||
Operating Lease, Right-of-Use Asset | 27,645 | $ 800 | ||
Operating Lease, Liability, Total | 29,729 | |||
Operating Lease, Expense | 2,800 | |||
Finance Lease, Right-of-use Asset, Accumulated Amortization | 2,500 | 2,300 | ||
Property, Plant and Equipment, Net [Member] | ||||
Finance Lease, Right-of-Use Asset | 5,300 | 5,000 | ||
Cost of Sales [Member] | ||||
Operating Lease, Expense | $ 1,800 | |||
Accounting Standards Update 2016-02 [Member] | ||||
Operating Lease, Right-of-Use Asset | 29,700 | |||
Operating Lease, Liability, Total | $ 33,600 | |||
Minimum [Member] | ||||
Lessee Operating Lease, Remaining Lease Term | 1 year | |||
Lessee, Operating Lease, Renewal Term | 1 year | |||
Maximum [Member] | ||||
Lessee Operating Lease, Remaining Lease Term | 5 years | |||
Lessee, Operating Lease, Renewal Term | 5 years | |||
Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member] | ||||
Depreciation, Depletion and Amortization, Nonproduction, Total | $ 800 | $ 1,600 | ||
DSM International B.V. [Member] | ||||
Manufacturing Capacity Reservation Fee Current | 24,400 | |||
Deferred Cost of Products Sold, Related Party | 13,800 | $ 3,300 | ||
Payments of Reservation Capacity Fees | $ 7,300 |
Note 2 - Balance Sheet Detail_3
Note 2 - Balance Sheet Details - Inventory, Current (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Raw materials | $ 2,451 | $ 3,901 |
Work-in-process | 238 | 539 |
Finished goods | 5,797 | 5,253 |
Inventories | $ 8,486 | $ 9,693 |
Note 2 - Balance Sheet Detail_4
Note 2 - Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Deferred cost of products sold - related party | $ 1,489 | $ 489 |
Deferred cost of products sold, noncurrent - related party | 9,001 | 2,828 |
Total | $ 10,490 | $ 3,317 |
Note 2 - Balance Sheet Detail_5
Note 2 - Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Prepayments, advances and deposits | $ 3,310 | $ 5,644 |
Recoverable taxes from Brazilian government entities | 956 | 631 |
Other | 3,949 | 4,291 |
Total prepaid expenses and other current assets | $ 8,215 | $ 10,566 |
Note 2 - Balance Sheet Detail_6
Note 2 - Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Property, plant and equipment | $ 100,702 | $ 98,387 |
Less: accumulated depreciation and amortization | (79,144) | (78,631) |
Property, plant and equipment, net | 21,558 | 19,756 |
Machinery and Equipment [Member] | ||
Property, plant and equipment | 45,874 | 43,713 |
Leasehold Improvements [Member] | ||
Property, plant and equipment | 39,951 | 39,922 |
Computer Equipment and Software [Member] | ||
Property, plant and equipment | 10,138 | 9,987 |
Furniture and Office Equipment, Vehicles and Land [Member] | ||
Property, plant and equipment | 3,279 | 3,016 |
Construction in Progress [Member] | ||
Property, plant and equipment | $ 1,460 | $ 1,749 |
Note 2 - Balance Sheet Detail_7
Note 2 - Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019USD ($) | ||
Cash paid for operating lease liabilities | $ 5,305 | |
Right-of-use assets obtained in exchange for new operating lease obligations(1) | $ 30,472 | [1] |
Weighted-average remaining lease term (in years) (Year) | 2 years 255 days | |
Weighted-average discount rate | 18.00% | |
[1] | Includes $26.7 million for operating leases existing on January 1, 2019 and $0.9 million for operating leases that commenced in the first quarter of 2019. |
Note 2 - Balance Sheet Detail_8
Note 2 - Balance Sheet Details - Maturities of Financing and Operating Leases (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
2019 (remaining nine months), financing leases | $ 368 | |
2019 (remaining nine months), operating leases | 12,755 | |
2019 (remaining nine months), total leases | 13,123 | |
2020, financing leases | 199 | |
2020, operating leases | 9,109 | |
2020, total leases | 9,308 | |
2021, financing leases | 1 | |
2021, operating leases | 7,226 | |
2021, total leases | 7,227 | |
2022, financing leases | ||
2022, operating leases | 7,398 | |
2022, total leases | 7,398 | |
2023, financing leases | ||
2023, operating leases | 3,034 | |
2023, total leases | 3,034 | |
Thereafter, financing leases | ||
Thereafter, operating leases | ||
Thereafter, total leases | ||
Total lease payments, financing leases | 568 | |
Total lease payments, operating leases | 39,522 | |
Total lease payments, total leases | 40,090 | |
Less: amount representing interest | (23) | |
Less: amount representing interest | (9,793) | |
Less: amount representing interest | (9,816) | |
Total lease liability, financing leases | 545 | |
Total lease liability, operating leases | 29,729 | |
Total lease liability, total leases | 30,274 | |
Current lease liability, financing leases | 452 | |
Current lease liability, operating leases | 10,972 | |
Current lease liability, total leases | 11,424 | |
Noncurrent lease liability, financing leases | 93 | |
Noncurrent lease liability, operating leases | 18,757 | |
Noncurrent lease liability, total leases | 18,850 | |
Total lease liability, financing leases | 545 | |
Operating Lease, Liability, Total | $ 29,729 |
Note 2 - Balance Sheet Detail_9
Note 2 - Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Contingent consideration | $ 4,286 | $ 4,286 |
Deposits | 145 | 2,465 |
Other | 1,117 | 1,207 |
Other assets | $ 5,548 | $ 7,958 |
Note 2 - Balance Sheet Detai_10
Note 2 - Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
DSM manufacturing capacity fee | $ 7,250 | |
Contract termination fees | 5,337 | 6,247 |
Accrued interest | 7,094 | 3,853 |
Payroll and related expenses | 5,285 | 9,220 |
Asset retirement obligation | 3,111 | 3,063 |
Tax-related liabilities | 2,589 | 2,139 |
Professional services | 1,871 | 1,173 |
Other | 1,054 | 3,284 |
Total accrued and other current liabilities | $ 33,591 | $ 28,979 |
Note 2 - Balance Sheet Detai_11
Note 2 - Balance Sheet Details - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Contract termination fees, net of current portion | $ 8,207 | $ 7,715 |
Liability for unrecognized tax benefit | 6,582 | 6,582 |
Contract liability, net of current portion (Note 9) | 1,449 | 1,587 |
Deferred rent, net of current portion(1) | 6,440 | |
Other | 682 | 868 |
Total other noncurrent liabilities | $ 16,920 | $ 23,192 |
Note 3 - Fair Value Measureme_3
Note 3 - Fair Value Measurement (Details Textual) | 3 Months Ended | ||
Mar. 31, 2019USD ($) | Dec. 31, 2018USD ($) | Dec. 10, 2018USD ($) | |
Long-term Debt, Gross | $ 229,272,000 | $ 228,921,000 | |
Long-term Debt, Fair Value | 60,048,000 | $ 57,918,000 | |
Debt, Long-term and Short-term, Combined Amount, Total | 155,800,000 | ||
Debt Instrument, Fair Value Disclosure, Total | 155,800,000 | ||
Convertible Senior Notes, 6.0% Due in 2021 [Member] | |||
Debt Instrument, Face Amount | $ 60,000,000 | ||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | 6.00% | |
Long-term Debt, Gross | 60,000,000 | ||
Long-term Debt, Fair Value | 60,000,000 | ||
Fair Value Adjustment of Debt | $ (2,100,000) | ||
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Discount Rate [Member] | |||
Long-term Debt, Measurement Input | 0.238 | ||
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Price Volatility [Member] | |||
Long-term Debt, Measurement Input | 0.45 | ||
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Probability of Principal Repayment in Cash [Member] | |||
Long-term Debt, Measurement Input | 0.5 | ||
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Probability of Principal Repayment in Stock [Member] | |||
Long-term Debt, Measurement Input | 0.5 | ||
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Probability of Change in Control [Member] | |||
Long-term Debt, Measurement Input | 0.05 |
Note 3 - Fair Value Measureme_4
Note 3 - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Debt, current portion, fair value | $ 60,048 | $ 57,918 |
Fair Value, Recurring [Member] | ||
Debt, current portion, fair value | 60,048 | 57,918 |
Freestanding derivative instruments in connection with the issuance of equity instruments | 3,798 | 42,796 |
Total liabilities measured and recorded at fair value | 63,846 | 100,714 |
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Debt, current portion, fair value | ||
Freestanding derivative instruments in connection with the issuance of equity instruments | ||
Total liabilities measured and recorded at fair value | ||
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Debt, current portion, fair value | ||
Freestanding derivative instruments in connection with the issuance of equity instruments | ||
Total liabilities measured and recorded at fair value | ||
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Debt, current portion, fair value | 60,048 | 57,918 |
Freestanding derivative instruments in connection with the issuance of equity instruments | 3,798 | 42,796 |
Total liabilities measured and recorded at fair value | $ 63,846 | $ 100,714 |
Note 3 - Fair Value Measureme_5
Note 3 - Fair Value Measurement - Convertible Debt (Details) - Long-term Debt [Member] $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Fair value | $ 57,918 |
Change in fair value | 2,130 |
Fair value | $ 60,048 |
Note 3 - Fair Value Measureme_6
Note 3 - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Fair value | $ 42,796 |
Derecognition upon adoption of ASU 2017-11 | (41,037) |
Change in fair value | 2,039 |
Fair value | 3,798 |
Equity Securities [Member] | |
Fair value | 41,272 |
Derecognition upon adoption of ASU 2017-11 | (39,513) |
Change in fair value | 2,039 |
Fair value | 3,798 |
Debt Securities [Member] | |
Fair value | 1,524 |
Derecognition upon adoption of ASU 2017-11 | (1,524) |
Change in fair value | |
Fair value |
Note 4 - Debt (Details Textual)
Note 4 - Debt (Details Textual) - Second Tranche [Member] - Related Party Convertible Notes [Member] - USD ($) $ in Millions | Jul. 15, 2019 | Jan. 14, 2019 |
Debt Instrument, Cash Waiver Fee Amount Payable | $ 0.6 | |
Subsequent Event [Member] | ||
Debt Instrument, Interest Rate, Stated Percentage | 1.75% |
Note 4 - Debt - Debt Components
Note 4 - Debt - Debt Components (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Principal | $ 229,272,000 | $ 228,921,000 | |
Unamortized Debt Premium | (13,493,000) | (17,142,000) | |
Loss from change in fair value of debt | 48,000 | (2,082,000) | |
Net Balance | 215,827,000 | 209,697,000 | |
Net Balance | (153,752,000) | (147,677,000) | |
Net Balance | 62,075,000 | 62,020,000 | |
Convertible Senior Notes, 6.0% Due in 2021 [Member] | |||
Principal | 60,000,000 | ||
Convertible Debt [Member] | |||
Principal | 126,754,000 | 126,306,000 | |
Unamortized Debt Premium | (1,243,000) | (3,350,000) | |
Loss from change in fair value of debt | 48,000 | (2,082,000) | |
Net Balance | 125,559,000 | 120,874,000 | |
Convertible Debt [Member] | Convertible Senior Notes, 6.0% Due in 2021 [Member] | |||
Principal | 60,000,000 | 60,000,000 | |
Unamortized Debt Premium | |||
Loss from change in fair value of debt | 48,000 | (2,082,000) | |
Net Balance | 60,048,000 | 57,918,000 | |
Convertible Debt [Member] | The 2015 144A Notes [Member] | |||
Principal | 37,887,000 | 37,887,000 | |
Unamortized Debt Premium | (358,000) | (2,413,000) | |
Loss from change in fair value of debt | |||
Net Balance | 37,529,000 | 35,474,000 | |
Convertible Debt [Member] | The 2014 144A Notes [Member] | |||
Principal | 24,004,000 | 24,004,000 | |
Unamortized Debt Premium | (289,000) | (867,000) | |
Loss from change in fair value of debt | |||
Net Balance | 23,715,000 | 23,137,000 | |
Convertible Debt [Member] | August 2013 Convertible Notes [Member] | |||
Principal | 4,863,000 | 4,415,000 | |
Unamortized Debt Premium | (596,000) | (70,000) | |
Loss from change in fair value of debt | |||
Net Balance | 4,267,000 | 4,345 | |
Related Party Convertible Notes [Member] | The 2014 144A Notes [Member] | |||
Principal | 24,705,000 | 24,705,000 | |
Unamortized Debt Premium | (346,000) | (1,038,000) | |
Loss from change in fair value of debt | |||
Net Balance | 24,359,000 | 23,667,000 | |
Nonrelated Party Debt [Member] | |||
Principal | 36,000,000 | 36,000,000 | |
Unamortized Debt Premium | (1,208,000) | (1,349,000) | |
Loss from change in fair value of debt | |||
Net Balance | 34,792,000 | 34,651,000 | |
Loans Payable [Member] | |||
Principal | 52,813,000 | 52,910,000 | |
Unamortized Debt Premium | (6,051,000) | (6,443,000) | |
Loss from change in fair value of debt | |||
Net Balance | 46,762,000 | 46,467,000 | |
Loans Payable [Member] | Ginkgo Collaboration Note [Member] | |||
Principal | 12,000,000 | 12,000,000 | |
Unamortized Debt Premium | (3,832,000) | (4,047,000) | |
Loss from change in fair value of debt | |||
Net Balance | 8,168,000 | 7,953,000 | |
Loans Payable [Member] | Other Loans Payable [Member] | |||
Principal | 4,813,000 | 4,910,000 | |
Unamortized Debt Premium | (1,011,000) | (1,047,000) | |
Loss from change in fair value of debt | |||
Net Balance | 3,802,000 | 3,863,000 | |
Related Party Loan Payable [Member] | DSM Note [Member] | |||
Principal | 25,000,000 | 25,000,000 | |
Unamortized Debt Premium | (5,853,000) | (6,311,000) | |
Loss from change in fair value of debt | |||
Net Balance | $ 19,147,000 | $ 18,689,000 |
Note 4 - Debt - Long-term Debt
Note 4 - Debt - Long-term Debt Instruments (Details) $ in Thousands | Mar. 31, 2019USD ($) |
2019 (remaining nine months) | $ 176,485 |
2020 | 12,613 |
2021 | 62,922 |
2022 | 13,450 |
2023 | 399 |
Thereafter | 2,268 |
Total future minimum payments | 268,137 |
Less: amount representing interest | (38,620) |
Less: future conversion of accrued interest to principal | (245) |
Present value of minimum debt payments | 229,272 |
Less: current portion of debt principal | (155,973) |
Noncurrent portion of debt principal | 73,299 |
Convertible Debt [Member] | |
2019 (remaining nine months) | 139,303 |
2020 | |
2021 | |
2022 | |
2023 | |
Thereafter | |
Total future minimum payments | 139,303 |
Less: amount representing interest | (12,303) |
Less: future conversion of accrued interest to principal | (245) |
Present value of minimum debt payments | 126,755 |
Less: current portion of debt principal | (126,755) |
Noncurrent portion of debt principal | |
Loans Payable and Credit Facilities [Member] | |
2019 (remaining nine months) | 9,689 |
2020 | 10,113 |
2021 | 34,776 |
2022 | 13,450 |
2023 | 399 |
Thereafter | 2,268 |
Total future minimum payments | 70,695 |
Less: amount representing interest | (17,883) |
Less: future conversion of accrued interest to principal | |
Present value of minimum debt payments | 52,812 |
Less: current portion of debt principal | (4,513) |
Noncurrent portion of debt principal | 48,299 |
Related Party Convertible Notes [Member] | |
2019 (remaining nine months) | 25,618 |
2020 | |
2021 | |
2022 | |
2023 | |
Thereafter | |
Total future minimum payments | 25,618 |
Less: amount representing interest | (913) |
Less: future conversion of accrued interest to principal | |
Present value of minimum debt payments | 24,705 |
Less: current portion of debt principal | (24,705) |
Noncurrent portion of debt principal | |
Related Party Loans Payable and Credit Facilities [Member] | |
2019 (remaining nine months) | 1,875 |
2020 | 2,500 |
2021 | 28,146 |
2022 | |
2023 | |
Thereafter | |
Total future minimum payments | 32,521 |
Less: amount representing interest | (7,521) |
Less: future conversion of accrued interest to principal | |
Present value of minimum debt payments | 25,000 |
Less: current portion of debt principal | |
Noncurrent portion of debt principal | $ 25,000 |
Note 5 - Mezzanine Equity (Deta
Note 5 - Mezzanine Equity (Details Textual) - Gates Foundation Purchase Agreement [Member] - USD ($) $ / shares in Units, $ in Millions | Apr. 08, 2016 | Mar. 31, 2019 |
Share Price | $ 17.10 | |
Compound Annual Return | 10.00% | |
Research and Development Obligation, Remaining Amount | $ 0.6 |
Note 5 - Mezzanine Equity - Mez
Note 5 - Mezzanine Equity - Mezzanine Equity (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Mezzanine Equity | $ 5,000 | $ 5,000 |
Contingently Redeemable Common Stock [Member] | ||
Mezzanine Equity | $ 5,000 | $ 5,000 |
Note 6 - Stockholders' Defici_2
Note 6 - Stockholders' Deficit (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Stock Issued During Period, Shares, Warrants Exercised | 479,751 | |
Proceeds from Warrant Exercises | $ 1 | $ 133 |
August 2017 Vito Dilution Warrants [Member] | ||
Stock Issued During Period, Shares, Warrants Exercised | 479,751 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | |
Proceeds from Warrant Exercises | $ 0 | |
Stock Issued During Period, Shares, Warrants Exercised Through Net Share Settlement | 450,568 |
Note 6 - Stockholders' Defici_3
Note 6 - Stockholders' Deficit - Warrant Activity (Details) | 3 Months Ended |
Mar. 31, 2019shares | |
Number outstanding, beginning balance (in shares) | 26,891,512 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | (479,751) |
Number outstanding, ending balance (in shares) | 26,411,761 |
Warrant 6 [Member] | |
Number outstanding, beginning balance (in shares) | 12,097,164 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | |
Number outstanding, ending balance (in shares) | 12,097,164 |
Warrant 4 [Member] | |
Number outstanding, beginning balance (in shares) | 6,292,798 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | |
Number outstanding, ending balance (in shares) | 6,292,798 |
Warrant 5 [Member] | |
Number outstanding, beginning balance (in shares) | 3,968,116 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | |
Number outstanding, ending balance (in shares) | 3,968,116 |
Warrant 7 [Member] | |
Number outstanding, beginning balance (in shares) | 3,616,174 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | |
Number outstanding, ending balance (in shares) | 3,616,174 |
Warrant 2 [Member] | |
Number outstanding, beginning balance (in shares) | 663,228 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | (471,204) |
Number outstanding, ending balance (in shares) | 192,024 |
Warrant 3 [Member] | |
Number outstanding, beginning balance (in shares) | 171,429 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | |
Number outstanding, ending balance (in shares) | 171,429 |
Warrant 1 [Member] | |
Number outstanding, beginning balance (in shares) | 81,197 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | (8,547) |
Number outstanding, ending balance (in shares) | 72,650 |
Warrant 8 [Member] | |
Number outstanding, beginning balance (in shares) | 1,406 |
Additional Warrants Issued (in shares) | |
Exercises (in shares) | |
Number outstanding, ending balance (in shares) | 1,406 |
Note 7 - Loss Per Share - Calcu
Note 7 - Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Net loss | $ (66,243) | $ (92,802) |
Less: losses allocated to participating securities | 2,430 | 7,504 |
Net loss attributable to Amyris, Inc. common stockholders | $ (63,813) | $ (85,298) |
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares) | 77,512,059 | 51,200,922 |
Loss per share attributable to common stockholders, basic and diluted (in dollars per share) | $ (0.82) | $ (1.67) |
Note 7 - Loss Per Share - Antid
Note 7 - Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | ||
Antidilutive securities (in shares) | 52,988,063 | 44,683,172 | |
Stock Options to Purchase Common Stock [Member] | |||
Antidilutive securities (in shares) | 5,427,384 | 1,365,447 | |
Convertible Promissory Notes [Member] | |||
Antidilutive securities (in shares) | [1] | 12,699,607 | 8,347,364 |
Period-end Common Stock Warrants [Member] | |||
Antidilutive securities (in shares) | 26,411,761 | 29,759,452 | |
Restricted Stock Units (RSUs) [Member] | |||
Antidilutive securities (in shares) | 5,493,579 | 706,697 | |
Period-end Preferred Stock [Member] | |||
Antidilutive securities (in shares) | 2,955,732 | 4,504,212 | |
[1] | The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 9 - Revenue Recognition _3
Note 9 - Revenue Recognition and Contract Assets and Liabilities 1 (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Contract with Customer, Asset, Reclassified to Receivable | $ 8,000 | |
Cost of Goods and Services Sold, Total | 17,707 | $ 5,315 |
Interest Expense, Total | 12,534 | $ 9,978 |
Revenue, Remaining Performance Obligation, Constrained Variable Consideration, Amount | 17,600 | |
DSM International B.V. [Member] | ||
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price | 600 | |
Proceeds from Customers | 7,400 | |
Interest Expense, Total | 200 | |
DSM International B.V. [Member] | Licenses and Royalties [Member] | ||
Cost of Goods and Services Sold, Total | $ 400 |
Note 9 - Revenue Recognition _4
Note 9 - Revenue Recognition and Contract Assets and Liabilities 2 (Details Textual) | Mar. 31, 2019 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 273 days |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Note 9 - Revenue Recognition _5
Note 9 - Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Revenues | $ 14,374 | $ 17,859 | $ 17,859 |
Renewable Products [Member] | |||
Revenues | 11,884 | 5,195 | 5,195 |
Licenses and Royalties [Member] | |||
Revenues | 118 | 7,955 | 7,955 |
Grants and Collaborations [Member] | |||
Revenues | 2,372 | $ 4,709 | 4,709 |
UNITED STATES | |||
Revenues | 7,566 | 3,171 | |
UNITED STATES | Renewable Products [Member] | |||
Revenues | 7,073 | 1,962 | |
UNITED STATES | Licenses and Royalties [Member] | |||
Revenues | |||
UNITED STATES | Grants and Collaborations [Member] | |||
Revenues | 493 | 1,209 | |
Europe [Member] | |||
Revenues | 4,601 | 13,889 | |
Europe [Member] | Renewable Products [Member] | |||
Revenues | 2,854 | 2,434 | |
Europe [Member] | Licenses and Royalties [Member] | |||
Revenues | 118 | 7,955 | |
Europe [Member] | Grants and Collaborations [Member] | |||
Revenues | 1,629 | 3,500 | |
Asia [Member] | |||
Revenues | 1,968 | 678 | |
Asia [Member] | Renewable Products [Member] | |||
Revenues | 1,718 | 678 | |
Asia [Member] | Licenses and Royalties [Member] | |||
Revenues | |||
Asia [Member] | Grants and Collaborations [Member] | |||
Revenues | 250 | ||
South America [Member] | |||
Revenues | 220 | 21 | |
South America [Member] | Renewable Products [Member] | |||
Revenues | 220 | 21 | |
South America [Member] | Licenses and Royalties [Member] | |||
Revenues | |||
South America [Member] | Grants and Collaborations [Member] | |||
Revenues | |||
Other Area [Member] | |||
Revenues | 19 | 100 | |
Other Area [Member] | Renewable Products [Member] | |||
Revenues | 19 | 100 | |
Other Area [Member] | Licenses and Royalties [Member] | |||
Revenues | |||
Other Area [Member] | Grants and Collaborations [Member] | |||
Revenues |
Note 9 - Revenue Recognition _6
Note 9 - Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Revenues | $ 14,374 | $ 17,859 | $ 17,859 |
Significant Revenue Agreement [Member] | |||
Revenues | 6,204 | 12,739 | |
Firmenich [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 3,117 | 1,511 | |
Givaudan International, SA [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 1,575 | 2,576 | |
American Refining Group [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 1,494 | ||
DSM International B.V. [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 18 | 8,652 | |
All Other Customers [Member] | |||
Revenues | 8,170 | 5,120 | |
Renewable Products [Member] | |||
Revenues | 11,884 | 5,195 | 5,195 |
Renewable Products [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 4,962 | 1,283 | |
Renewable Products [Member] | Firmenich [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 1,891 | 207 | |
Renewable Products [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 1,575 | 1,076 | |
Renewable Products [Member] | American Refining Group [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 1,494 | ||
Renewable Products [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 2 | ||
Renewable Products [Member] | All Other Customers [Member] | |||
Revenues | 6,922 | 3,912 | |
Licenses and Royalties [Member] | |||
Revenues | 118 | 7,955 | 7,955 |
Licenses and Royalties [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 118 | 7,955 | |
Licenses and Royalties [Member] | Firmenich [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 498 | 37 | |
Licenses and Royalties [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member] | |||
Revenues | |||
Licenses and Royalties [Member] | American Refining Group [Member] | Significant Revenue Agreement [Member] | |||
Revenues | |||
Licenses and Royalties [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member] | |||
Revenues | (380) | 7,918 | |
Licenses and Royalties [Member] | All Other Customers [Member] | |||
Revenues | |||
Grants and Collaborations [Member] | |||
Revenues | 2,372 | 4,709 | $ 4,709 |
Grants and Collaborations [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 1,124 | 3,501 | |
Grants and Collaborations [Member] | Firmenich [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 728 | 1,267 | |
Grants and Collaborations [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 1,500 | ||
Grants and Collaborations [Member] | American Refining Group [Member] | Significant Revenue Agreement [Member] | |||
Revenues | |||
Grants and Collaborations [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member] | |||
Revenues | 396 | 734 | |
Grants and Collaborations [Member] | All Other Customers [Member] | |||
Revenues | $ 1,248 | $ 1,208 |
Note 9 - Revenue Recognition _7
Note 9 - Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 | |
Accounts receivable, net | $ 10,968 | $ 16,003 | |
Accounts receivable - related party, net | 1,334 | 1,349 | |
Accounts receivable, unbilled - related party | 8,021 | ||
Accounts receivable, unbilled, noncurrent - related party | [1] | 1,203 | 1,203 |
Contract liabilities | 8,333 | 8,236 | |
Contract liabilities, noncurrent(1) | [1] | $ 1,449 | $ 1,587 |
[1] | As of March 31, 2019 and December 31, 2018, contract liabilities, noncurrent is presented in Other Noncurrent Liabilities in the consolidated balance sheets because of its insignificance. |
Note 9 - Revenue Recognition _8
Note 9 - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) $ in Millions | Mar. 31, 2019USD ($) |
Revenue, Remaining Performance Obligation, Amount | $ 93.6 |
Note 9 - Revenue Recognition _9
Note 9 - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations 2 (Details) $ in Thousands | Mar. 31, 2019USD ($) |
Revenue, Remaining Performance Obligation, Amount | $ 93,600 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 273 days |
Revenue, Remaining Performance Obligation, Amount | $ 23,920 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 38,508 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 31,172 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Revenue, Remaining Performance Obligation, Amount |
Note 10 - Related Party Trans_3
Note 10 - Related Party Transactions (Details Textual) | Mar. 31, 2019 |
Nikko [Member] | Aprinnova JV [Member] | |
Equity Method Investment, Ownership Percentage | 50.00% |
Note 10 - Related Party Trans_4
Note 10 - Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 | |
Accounts receivable, net | $ 1,334 | $ 1,349 | |
Contract assets, current | 8,021 | ||
Contract assets, noncurrent | [1] | 1,203 | 1,203 |
DSM International B.V. [Member] | |||
Accounts receivable, net | 1,334 | 1,071 | |
Contract assets, current | 8,021 | ||
Contract assets, noncurrent | 1,203 | 1,203 | |
Novvi LLC [Member] | |||
Accounts receivable, net | 188 | ||
Total [Member] | |||
Accounts receivable, net | $ 90 | ||
[1] | As of March 31, 2019 and December 31, 2018, contract liabilities, noncurrent is presented in Other Noncurrent Liabilities in the consolidated balance sheets because of its insignificance. |
Note 11 - Stock-based Compens_3
Note 11 - Stock-based Compensation (Details Textual) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 | |
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 31.1 | ||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 3 years | ||
Shares, Outstanding, Ending Balance | 76,564,829 | ||
Equity Incentive Plan, 2010 [Member] | |||
Automatic Annual Increase in the Number of Shares Available for Grant and Issuance | 3,828,241 | ||
Automatic Annual Increase in Shares Available for Grant and Issuance, Percentage of Outstanding Stock | 5.00% | ||
Automatic Annual Increase in the Number of Shares Reserved for Issuance | 383,824 | ||
Automatic Annual Increase in Shares Reserved for Issuance, Percentage of Outstanding Stock | 0.5 |
Note 11 - Stock-based Compens_4
Note 11 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2019 | Dec. 31, 2018 | |
Outstanding (in shares) | 5,390,270 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 11.55 | |
Outstanding, weighted average remaining contractual life (Year) | 8 years 109 days | 8 years 182 days |
Outstanding, aggregate intrinsic value | $ 29 | |
Granted (in shares) | 104,452 | |
Granted, weighted average exercise price (in dollars per share) | $ 4.73 | |
Exercised (in shares) | (3,612) | |
Exercised, weighted average exercise price (in dollars per share) | $ 3.68 | |
Forfeited or expired (in shares) | (63,726) | |
Forfeited or expired, weighted average exercise price (in dollars per share) | $ 14.27 | |
Outstanding (in shares) | 5,427,384 | 5,390,270 |
Outstanding, weighted average exercise price (in dollars per share) | $ 11.39 | $ 11.55 |
Vested or expected to vest (in shares) | 4,874,155 | |
Vested and expected to vest, weighted average exercise price (in dollars per share) | $ 12.10 | |
Vested and expected to vest, weighted average remaining contractual life (Year) | 8 years 109 days | |
Vested and expected to vest, aggregate intrinsic value | ||
Exercisable (in shares) | 977,466 | |
Exercisable, weighted average exercise price (in dollars per share) | $ 39.20 | |
Exercisable, weighted average remaining contractual life (Year) | 5 years 292 days | |
Exercisable, aggregate intrinsic value |
Note 11 - Stock-based Compens_5
Note 11 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2019 | Dec. 31, 2018 | |
Outstanding, RSUs (in shares) | 5,294,803 | |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 5.50 | |
Outstanding, weighted average remaining contractual life (Year) | 1 year 182 days | 1 year 255 days |
Awarded (in shares) | 493,790 | |
Awarded, weighted average grant-date fair value (in dollars per share) | $ 4.65 | |
RSUs released (in shares) | (192,795) | |
RSUs released, weighted average grant-date fair value (in dollars per share) | $ 6.55 | |
RSUs forfeited (in shares) | (102,219) | |
RSUs forfeited, weighted average grant-date fair value (in dollars per share) | $ 5.61 | |
Outstanding, RSUs (in shares) | 5,493,579 | 5,294,803 |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 5.38 | $ 5.50 |
Vested or expected to vest (in shares) | 5,153,107 | |
Vested or expected to vest, weighted average grant-date fair value (in dollars per share) | $ 5.39 | |
Vested or expected to vest, weighted average remaining contractual life (Year) | 1 year 182 days |
Note 11 - Stock-based Compens_6
Note 11 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Allocated share-based compensation expense | $ 3,452 | $ 1,278 |
Research and Development Expense [Member] | ||
Allocated share-based compensation expense | 663 | 363 |
Selling, General and Administrative Expenses [Member] | ||
Allocated share-based compensation expense | $ 2,789 | $ 915 |
Note 12 - Subsequent Events (De
Note 12 - Subsequent Events (Details Textual) | Sep. 23, 2019USD ($) | Sep. 10, 2019USD ($)$ / sharesshares | Aug. 19, 2019 | Aug. 14, 2019USD ($)$ / sharesshares | Aug. 08, 2019USD ($) | Jul. 30, 2019USD ($) | Jul. 26, 2019USD ($) | Jul. 24, 2019USD ($)$ / sharesshares | Jul. 08, 2019shares | Jun. 24, 2019USD ($)shares | May 15, 2019USD ($)$ / sharesshares | May 14, 2019USD ($)$ / sharesshares | May 10, 2019USD ($)$ / sharesshares | May 10, 2019BRL (R$)shares | May 03, 2019USD ($)$ / sharesshares | May 02, 2019USD ($) | Apr. 29, 2019USD ($)$ / sharesshares | Apr. 26, 2019USD ($)$ / sharesshares | Apr. 16, 2019USD ($)$ / sharesshares | Apr. 15, 2019USD ($) | Apr. 04, 2019USD ($) | Jun. 30, 2020USD ($) | Oct. 01, 2019 | Sep. 30, 2019 | Sep. 29, 2019USD ($) | Sep. 19, 2019USD ($) | Sep. 17, 2019USD ($) | Sep. 16, 2019USD ($) | Aug. 29, 2019USD ($)$ / shares | Aug. 28, 2019$ / shares | Aug. 01, 2019USD ($) | Jul. 29, 2019USD ($) | Jul. 18, 2019 | Jul. 10, 2019USD ($)$ / shares | Jun. 11, 2019USD ($) | Apr. 08, 2019USD ($) | Mar. 31, 2019USD ($) | Dec. 31, 2018USD ($) | Dec. 10, 2018USD ($) | Aug. 17, 2018$ / shares |
Long-term Debt, Gross | $ 229,272,000 | $ 228,921,000 | ||||||||||||||||||||||||||||||||||||||
Long-term Debt, Total | 215,827,000 | 209,697,000 | ||||||||||||||||||||||||||||||||||||||
July Foris Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 7.52 | |||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||
Long-term Debt, Gross | 126,754,000 | 126,306,000 | ||||||||||||||||||||||||||||||||||||||
Long-term Debt, Total | 125,559,000 | $ 120,874,000 | ||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 6.0% Due in 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | 6.00% | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 60,000,000 | |||||||||||||||||||||||||||||||||||||||
Long-term Debt, Gross | 60,000,000 | |||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||
Long-term Debt, Gross | 60,000,000 | $ 60,000,000 | ||||||||||||||||||||||||||||||||||||||
Long-term Debt, Total | 60,048,000 | 57,918,000 | ||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||
Long-term Debt, Gross | 4,863,000 | 4,415,000 | ||||||||||||||||||||||||||||||||||||||
Long-term Debt, Total | $ 4,267,000 | $ 4,345 | ||||||||||||||||||||||||||||||||||||||
DSM International B.V. [Member] | The 2019 DSM Credit Agreement [Member] | Forecast [Member] | ||||||||||||||||||||||||||||||||||||||||
Proceeds from Sale of Equity Securities, Gross, Trigger Repayment of Amounts Outstanding Under Line of Credit | $ 50,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Private Placement [Member] | ||||||||||||||||||||||||||||||||||||||||
Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage | 19.99% | |||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 5,000,000 | $ 5,800,000 | $ 23,200,000 | |||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | LSA Amendment Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,438,829 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 2.87 | |||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage | 19.99% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | July Foris Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 2.87 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise | 4.99% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | August Foris Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 4,871,795 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 3.90 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise | 19.99% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,000,000 | 181,818 | 2,000,000 | |||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5.12 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repayment Price, Percent of Face Amount | 4.99% | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Warrants Issued in Exchange for Convertible Senior Notes, 6.0% Due 2021, Second Exchange [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,000,000 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 2.87 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Warrants Issued in Exchange for August 2013 Financing Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,080,000 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise | 4.99% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Investor Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 3,205,128 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 3.90 | |||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Warrants or Rights Outstanding, Maximum Percent of Common Stock Outstanding | 9.99% | |||||||||||||||||||||||||||||||||||||||
Warrants or Rights Outstanding, Reduction in Exercise Price | 10.00% | |||||||||||||||||||||||||||||||||||||||
Warrants or Rights Outstanding, Additional Reduction in Exercise Price | 5.00% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Minimum [Member] | Investor Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 3.31 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | ||||||||||||||||||||||||||||||||||||||||
Related Party Transaction, Purchases from Related Party | $ 2,500,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Raizen Energia S.A. [Member] | ||||||||||||||||||||||||||||||||||||||||
Capital Contribution to the Joint Venture | R$ | R$ 2500000 | |||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 50.00% | |||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage by Counterparty | 50.00% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Raizen Energia S.A. [Member] | Fixed Assets Owned by the Company [Member] | ||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Property, Plant, and Equipment, Total | $ 9,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Raizen Energia S.A. [Member] | Fixed Assets From Sao Martinho S.A. [Member] | ||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Property, Plant, and Equipment, Total | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.75% | |||||||||||||||||||||||||||||||||||||||
Long-term Debt, Gross | $ 71,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | Unsecured Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 32,500,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | Base Rate [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 9.00% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | Base Rate [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 12.00% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Senior Notes, 6.0% Due in 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 68,300,000 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repayment Price, Percent of Face Amount | 125.00% | 125.00% | ||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 4,700,000 | $ 53,300,000 | $ 4,700,000 | $ 53,300,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Penalty for Failure to Make Payment, Premium Increase Percentage | 25.00% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment, Principal | $ 6,400,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Senior Notes, 6.0%, Due in 2021, Second Exchange [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18.00% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 68,300,000 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment, Principal | $ 3,200,000 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | $ 63,600,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | August 2013 Convertible Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 1,767,632 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Nikko Loan Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||||||||||||||||||||||||||||||||||||
Long-term Debt, Total | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Nikko Loan Agreement, First Installment [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt, Total | 2,800,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Nikko Loan Agreement, Second Installment [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt, Total | 1,900,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Second Aprinnova Note [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,018,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | The Naxyris Loan Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,435,000 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Failure to Pay Fee | 6.00% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | The Naxyris Loan Agreement [Member] | Interest Wtih Respect to Indebtedness [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 0.25% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | The Investor Notes [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 12,500,000 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Early Repayment Amount, Percentage | 100.00% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Secured Promissory Note In Connection With Termination of Ginkgo Collaboration Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 10.50% | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Cash Waiver Fee Amount Payable | $ 1,300,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Great American Capital Partners, LLC [Member] | Loan and Security Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Requirement, Unrestricted, Unencumbered Cash | $ 15,000,000 | |||||||||||||||||||||||||||||||||||||||
Payments for debt agreement amendment | $ 800,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 8,000,000 | |||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 8,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | 1,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 500,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | June Foris Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 8,500,000 | |||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 8,500,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | July Foris Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 8,000,000 | |||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 16,000,000 | |||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit, Total | $ 8,000,000 | $ 8,000,000 | ||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | Foris Credit Agreements [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repayment Price, Percent of Face Amount | 100.00% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | August Foris Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 19,000,000 | |||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 19,000,000 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repayment Price, Percent of Face Amount | 100.00% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | |||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 8,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, Second Installment [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Incremental Draw Down Amount | $ 3,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, Third Installment [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 1,500,000 | |||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Incremental Draw Down Amount | $ 2,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, First Installment [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 3,000,000 | |||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Incremental Draw Down Amount | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | The Investors [Member] | ||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 12,500,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement [Member] | ||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 2,832,440 | 6,732,369 | ||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 5.12 | $ 2.87 | ||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 20,000,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement, April 26, 2019 [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 3,983,230 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5.12 | $ 3.90 | $ 3.90 | |||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 4.56 | $ 3.90 | ||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants Issued | shares | 352,638 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement, April 16, 2019 [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 5,424,804 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 2.87 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | Rule 144A Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 1,122,460 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement [Member] | ||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 1,243,781 | 323,382 | 2,043,781 | |||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 4.02 | $ 4.02 | $ 4.02 | |||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement, April 26, 2019 [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,635,025 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5.02 | |||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5.02 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 2 years | 2 years | ||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants Issued | shares | 1,391,603 | 1,391,603 | ||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement April 29, 2019 [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 258,704 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5.02 | |||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement May 3, 2019 [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 995,024 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5.02 | |||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Rule 144A Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||
Repayments of Debt | $ 37,900,000 | |||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 13,500,000 | |||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 3,479,008 | 3,479,008 | ||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Vivo Capital LLC [Member] | Private Placement [Member] | ||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 913,529 | |||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 4.76 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Vivo Capital LLC [Member] | Private Placement April 29, 2019 [Member] | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,212,787 | |||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 4.76 | |||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 2 years | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||||||||||||||||||
Consideration Transferred | 57,000,000 | |||||||||||||||||||||||||||||||||||||||
Consideration Transferred, Cash Amount | 29,100,000 | |||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 27,900,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Maxwell (Mauritius) Pte Ltd [Member] | Rule 144A Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 2,500,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Total [Member] | Rule 144A Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.50% | |||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement [Member] | Aprinnova JV [Member] | ||||||||||||||||||||||||||||||||||||||||
First Priority Lien on Interests Owned by the Company | 12.80% | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement, First Installment [Member] | ||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt, Withheld as Prepayment of Interest Payable | $ 200,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement, Second Installment [Member] | ||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt, Withheld as Prepayment of Interest Payable | $ 100,000 | |||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | The Cannabinoid Agreement [Member] | Lavvan [Member] | ||||||||||||||||||||||||||||||||||||||||
Agreement Amount | $ 300,000,000 | |||||||||||||||||||||||||||||||||||||||
Agreement, Amount of Research and Development Funding that Could Be Received | $ 300,000,000 | |||||||||||||||||||||||||||||||||||||||
Agreement, Profit Sharing to Be Received from the Counterparty, Period | 20 years |